Want to see QTTB full AI Analyst Report?
Top Page
Q32 Bio
(NASDAQ:QTTB)
Select Model
Select Model
Rating:67Neutral
Price Target:
$17.50
▲(15.51% Upside)
Action:Downgraded
Date:08/05/26
The score is driven primarily by mixed financial quality (improved reported profitability and healthier leverage, but materially negative operating/free cash flow and historical volatility). Technicals are a strong positive with price above major moving averages and supportive MACD/RSI. Valuation appears favorable via a low P/E, and recent corporate updates are constructive due to positive Phase 2a data and added funding.
Positive Factors
Clinical proof-of-concept
Robust Phase 2a topline results give durable clinical proof-of-concept for bempikibart’s IL-7Rα approach, showing efficacy and a favorable safety profile. This materially lowers development risk, enables a registration-directed path and broader indication expansion potential over the next 2–3 years.
Negative Factors
Negative cash generation
Sustained negative operating and free cash flow means R&D and trial execution are not self-funded. Persistent cash burn forces recurring capital raises, increases dilution risk, and makes program timelines sensitive to capital market conditions and investor appetite over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical proof-of-concept
Robust Phase 2a topline results give durable clinical proof-of-concept for bempikibart’s IL-7Rα approach, showing efficacy and a favorable safety profile. This materially lowers development risk, enables a registration-directed path and broader indication expansion potential over the next 2–3 years.
Read all positive factors
Q32 Bio (QTTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$471.55M
Dividend YieldN/A
Average Volume (3M)1.83M
Price to Earnings (P/E)5.7
Beta (1Y)0.28
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.79
Shares Outstanding29,769,466
10 Day Avg. Volume4,533,254
30 Day Avg. Volume1,831,587
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$42.75Price Target Upside182.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$1.25M
Q32 Bio Business Overview & Revenue Model
Company Description
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disord...
How the Company Makes Money
Q32 Bio is a clinical-stage biotech and, as such, it does not primarily generate revenue from selling approved products. Its funding typically comes from external financing and strategic sources rather than operating sales. Specific, company-verif...
Q32 Bio Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.74M | 53.74M | 0.00 | -6.65M | 6.65M | 0.00 |
| Gross Profit | 53.74M | 53.74M | 0.00 | -6.65M | 6.65M | 0.00 |
| EBITDA | 34.62M | 31.31M | -44.50M | -47.76M | -38.85M | -36.65M |
| Net Income | 33.79M | 29.82M | -47.73M | -53.74M | -42.81M | -37.56M |
Balance Sheet | ||||||
| Total Assets | 115.87M | 61.78M | 92.33M | 47.06M | 229.53M | 211.72M |
| Cash, Cash Equivalents and Short-Term Investments | 106.27M | 48.30M | 77.97M | 25.62M | 175.03M | 155.87M |
| Total Debt | 5.30M | 15.34M | 18.90M | 50.84M | 29.95M | 23.93M |
| Total Liabilities | 9.96M | 19.76M | 86.66M | 229.98M | 51.54M | 42.07M |
| Stockholders Equity | 105.91M | 42.01M | 5.67M | -182.92M | 177.98M | 169.65M |
Cash Flow | ||||||
| Free Cash Flow | -19.83M | -33.54M | -67.79M | -18.68M | -13.44M | -112.15M |
| Operating Cash Flow | -19.83M | -33.54M | -67.72M | -18.68M | -10.96M | -109.75M |
| Investing Cash Flow | 7.00M | 7.00M | 19.93M | -5.00K | -2.47M | -50.79M |
| Financing Cash Flow | 64.27M | -3.13M | 95.14M | 406.00K | 30.07M | 52.17M |
Q32 Bio Technical Analysis
Positive
15.15
Price Trends
14.49
Positive
10.79
Positive
7.35
Positive
Market Momentum
0.34
Positive
54.31
Neutral
44.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Positive. The current price of 15.15 is below the 20-day moving average (MA) of 15.57, above the 50-day MA of 14.49, and above the 200-day MA of 7.35, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 54.31 is Neutral, neither overbought nor oversold. The STOCH value of 44.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QTTB.
Q32 Bio Risk Analysis
Q32 Bio disclosed 84 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Q32 Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $471.55M | 5.68 | 76.88% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $46.28M | -1.70 | -35.78% | ― | ― | -43.60% | |
45 Neutral | $11.23M | -0.33 | -346.03% | ― | ― | 30.16% | |
43 Neutral | $17.10M | -0.23 | -729.89% | ― | ― | 69.34% | |
41 Neutral | $20.93M | -0.42 | 4092.98% | ― | ― | 15.37% | |
41 Neutral | $14.42M | -0.25 | -503.79% | ― | ― | 80.28% |
* Healthcare Sector Average
QTTB
Q32 Bio
15.86
13.95
730.37%
TPST
Tempest Therapeutics
1.02
-9.00
-89.82%
PDSB
PDS Biotechnology
0.21
-0.98
-82.52%
GRCE
Grace Therapeutics
2.14
-1.11
-34.15%
CALC
CalciMedica
0.58
-2.20
-79.03%
SNTI
Senti Biosciences
0.44
-1.20
-73.41%
Q32 Bio Corporate Events
Business Operations and Strategy
Q32 Bio Reports Positive Phase 2a Alopecia Areata Results
Positive
Jul 13, 2026
On July 13, 2026, Q32 Bio announced topline 36‑week results from Part B of its Phase 2a SIGNAL‑AA trial of bempikibart in alopecia areata, showing robust clinical activity and a favorable safety profile with no Grade 3 or higher advers...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Q32 Bio Reports Positive Alopecia Phase 2a Data
Positive
Jul 13, 2026
On July 13, 2026, Q32 Bio reported positive 36-week topline data from Part B of its SIGNAL-AA Phase 2a trial testing bempikibart in 33 patients with severe or very severe alopecia areata, including those previously treated with JAK inhibitors. The...
Executive/Board ChangesShareholder Meetings
Q32 Bio Shareholders Back Directors, Auditor and Executive Pay
Positive
Jun 16, 2026
At Q32 Bio Inc.’s 2026 Annual Meeting of Stockholders, held with approximately 75.71% of eligible common shares represented, investors elected Class II directors Kathleen LaPorte, Jodie Morrison and Arthur Tzianabos, Ph.D., to three-year ter...
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Raises $55 Million in Private Placement
Positive
May 27, 2026
On May 26, 2026, Q32 Bio Inc. signed a securities purchase agreement with institutional and other accredited investors for a private placement of 6,725,000 common shares at $8.00 each and pre-funded warrants for 150,000 additional shares, for expe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.